Presented by: Steven Victor

Chief Executive Officer

Regenerative Curative Preventative
InvestorPresentation
Safe Harbor
1
Statements in this presentation that are not descriptions of historical facts are forward-looking
statements relating to future events, and as such all forward-looking statements are made
pursuant to the Securities Litigation Reform Act of 1995. Statements may contain certain
forward-looking statements pertaining to future anticipated or projected plans, performance
and developments, as well as other statements relating to future operations and results. Any
statements in this presentation that are not statements of historical fact may be considered to
be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate,"
"estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar
words, identify forward-looking statements. These forward-looking statements by their nature
are estimates of future results only and involve substantial risks and uncertainties, including
but not limited to risks associated with the uncertainty of future financial results, additional
financing requirements, development of new products, successful completion of the
Companys proposed restructuring, the impact of competitive products or pricing, technological
changes, the effect of economic conditions and other uncertainties detailed from time to time
in our reports filed with the Securities and Exchange Commission. There can be no assurance
that our actual results will not differ materially from expectations and other factors more fully
described in our public filings with the U.S. Securities and Exchange Commission, which can
be reviewed at www.sec.gov.
INTELLICELL BIOSCIENCES
Research began in 2009 and Company
founded in 2010
Cellular laboratory in New York and
planned location in Florida
New facilities and planned in major
US markets
2
Cellular Processing Laboratory
IntelliCell has first commercial cellular processing laboratory
integrated into an ASC suite in NYC
Capability to treat multiple disease and injury states under the
practice of medicine
Facility meets regulatory requirements for cGTP processing
Can be deployed in major markets in US and Internationally
Hospital/Ambulatory Surgery Center
Labs
Business Model
Business Model
The company will install/build a FDA cGTP lab in a 25 x 25 foot
room
The company will employee a QC technician that it trains and
monitors
The QA of the lab would be accomplished via NY QA director
All SOPs would be handled by Company
The Company would sell cells for $2,500 and the
physician/hospital would charge patient fee set by them if the
hospital pays for the lab BUT if Intellicell pays for lab do a 50/50
revenue share
All samples would be total QA
Cells available to all and any specialties
Company would arrange CME courses
5
Why doctors would use cells
Continuing Medical Education
The company will conduct continuing medical education course to
multiple specialties in order to teach physicians about cellular
therapy
The CME course will also expose the physicians to the availability
of Intellicells cellular product to treat their patients under the
practice of medicine
7
Clinical Experience
Summary of Results for SVF Treatments
OVER 400 PATIENTS TREATED WITH SVF
NO ADVERSE REACTIONS TO ANY SVF TREATMENT
4 LOCAL INFECTIONS AT PUNCTURE SITE OF HARVESTING
(DUE TO POOR WOUND CARE BY PATIENT)
8
PHYSICIAN GROUP MEDICAL PRACTICE
Cosmetic Dermatologist
Cosmetic / Plastic Surgeon
Ear Nose & Throat Specialist
Internal Medicine Specialist
3 Orthopedic Specialists
Neuropsychiatrist
Anecdotal Clinical Results
ALS- QEEG Scans
10
MRI Indicating Positive Changes in OA Hip
11
Skiing fracture
12
MultipleFractures
WastoldneverraceagainBUT
racing in6months
13
New York Daily News
The J ournal of Implant & Advanced
Clinical Dentistry
14
Volume Filling
& wrinkles
15
FreshFat+SVFs
Treatment for Bells Palsy
16 Weeks After Treatment
BellsPalsy
NerveDroop
Nomoredroop
62yroldType1Diabeticdiagnosedwith
permanentBellsPalsy
Currently
Pre-
treatmentSeSe
One Hour Later
MARKET OPPORTUNITY
Market Indications
$15 billion current market for Regenerative Medicine
1.2 million patients to date treated with RM products and therapies
400 + private and 50 public companies with $4.7 billion in total market cap
175,000 peer-reviewed publications and 10,000 issued or pending patents
400 products in the market today with 600 more in development
Proliferation of patient advocacy groups demanding shift to RM
$1.5 billion in worldwide research funding projected to $14 billion in 10 years
Potential market is LARGELY UNTAPPED
Projected to reach $300 billion by 2020
source: US Department of Health and Human Services
19
AND THATS JUST THE BEGINNING
Partial List of Potential Treatable Conditions
Osteoarthritis
Internal Medicine
Gum Regeneration
Periodontal
Diabetic Ulcers
Wound healing
Multiple Sclerosis
Parkinsons
Internal Medicine
Cartilage Regeneration
Severe Burns
20
Orthopedic and Sports Medicine
Tendon Repair
Facial Lines and Wrinkles
Aesthetic Medicine
Heart Damage
Chronic Migraine Headache
Nerve Damage
Bone Regeneration
General Surgery
Hair Regeneration
Blindness and Deafness
Regenerative Medicine can offer new options and improved outcomes
THE INTELLICELL SCIENCE
Stromal Vascular Fraction (SVF)
Intellicells therapies use Adult Stromal Vascular Cells
Derived from Blood Vessels in adipose tissue
Capillaries are primary source
Same-day clinical procedure
High cell counts
22
Blood vessels
Adipose (fat) cells
Capillaries
SVF cellular composition:
Adult adipose stem cells
Pre-adipocyte cells
Endothelial cells
Smooth muscle cells
Pericytes
Fibroblasts
Growth factors Blood Cells from capillaries:
B &T cells
M2 Macrophages (anti-inflammatory)
Monocytes
Mast cells
Natural killer (NK) cells
Hematopoietic stem cells
Endothelial progenitor cells
The Intellicell Process (patent pending)
23
Enzymatic
Extraction
Ultrasonic
Cavitation
Typical
Method Intellicell Method
Typical Manufacturing Process:
SVF is manufactured from adipose tissue using collagenase enzymes,
particularly Liberase manufactured by Roche
Intellicell Innovation:
We discovered and pioneered the use of ultrasonic cavitation to
manufacture SVF from adipose tissue
The IntelliCell Ultrasound Cavitation R & D
Over 3 years in development
Over 700 tissue samples studied
Several mechanical systems tested, ultrasound emerged as best
Significant trial and error required to perfect the process
Resulted in a process that yields large cell numbers per cc of
tissue harvested
Resulted in a process that demonstrates high cell viability
24
Ultrasonic Cavitation
Enzymatic Extraction
Typical Method vs. Intellicell Method
25
Cells per ML: 3-8 Million
Dead Cells: 15-30%
Debris: 5-15%
Total Volume of cells: 20 cc
Total Dose: 50-70 Million Cells
Cells per ML: 20-30 Million
Dead Cells: 5-8%
Debris: 2-6%
Total Volume of Cells: 40-50 cc
Total Dose: 500 Million - 1 Billion
COSTOFDISPOSABLES:$150
MANUFACTURINGTIME:45to 60MINUTES
COSTOFDISPOSABLES:asmuchas$1500
MANUFACTURINGTIME:60to120MINUTES
Extracting SVF from 60 CC of adipose tissue
MANUFACTURING PROCESS
IntelliCellCell Process
27
Inject into
site of ailment
Administer
intravenously
28
Lab Procedures
All SVF manufactured under FDA "current Good Tissue Practices" (cGTP)
IntelliCell has a Director of QA to ensure all procedures fully compliant
Each specimen produced will have to be released by a QA manager
For remote sites we will employ a Modular Clean Room set up or build out a
cGTP lab
Aseptic Containment Isolator
meets all FDA tissue handling requirements
29
Evaluation Using a Flow Cytometer
laser that measures cell count and viability
Release Criteria for use of SVF
FLOW CYTOMETRY: 80%+ Viability
ENDOTOXIN TESTING: within standards
GRAM STAIN: negative
Additional testing:
14-day sterility assay
intra-process plating
Patent Granted
30
U.S. Patent 8,440,440 & International Patent Application PCT/US2011/64464
"ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS
AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF"
U.S. Provisional Application No. 61/674,116
"ISOLATION OF STROMAL VASCULAR FRACTION FROMADIPOSE TISSUE OBTAINED FROM
A NON-LIVING SOURCE USING ULTRASONIC CAVITATION"
Intellicell will be filing additional patents
Companys Cellular Product
FDA
FDA Major Conclusion Points
Our Lab process falls under FDA CFR 1271.10 (a) and
therefore we believe PHS 361 exempt
Also the cells are utilized under CFR 1271.15 (b) and any
clinical claims are made by the physician under the practice
of medicine
We operate a fully validated FDA cGTP laboratory with strict
SOPs
All our cellular samples are subject to strict QA release
criteria and our product is sterile and traceable
32
MANAGEMENT
&
ADVISORS
Management
34
Dr. Steven Victor, Chairman and CEO
Dr. Steven Victor, founder and CEO of IntelliCell, has been at the forefront of clinical product and process development
for over 20 years. The patent pending process that Dr. Victor has developed for IntelliCell has been in research for over
4 years. Dr. Victor is a practicing dermatologist in New York City. Dr. Victor's work in regenerative medicine began over
a decade ago upon the start of clinical use of autologous fibroblast cells for the purpose of dermal regeneration. Dr.
Victor received his medical degree from New York College and a Bachelor of Arts degree from New York University
and has held hospital-based teaching positions. He has been sought after to teach physicians new clinical techniques
worldwide for over 20 years. Dr. Victor has also been featured in international and local media as an expert in
regenerative medicine, medical aesthetics and dermatology.
Leonard Mazur, Chief Operating Officer
Mr. Mazur also serves as an independent Board of Director and is presently the COO of Akrimax Pharma and former
COO of Trimaz Pharma. He was CEO of Genesis Pharma sold to Pierre Fabre. At Medicus Pharma he was Ex VP of
Sales and Marketing
Anna Rhodes, Executive VP Operations
Ms. Rhodes has been actively involved in the cosmetic and cosmeceuticals industries for over 9 years. From 2001
through 2009, Ms. Rhodes held various executive sales and marketing positions with Victor Cosmeceuticals, Inc. and
Victor Products Inc., developing marketing and collateral materials, formulations and training materials for new product
launches as well as managing domestic and international distribution. Prior to 2001, Ms. Rhodes held corporate
executive managerial and sales positions in the high fashion industry with companies including Calvin Klein, Alberta
Ferretti, Michael Kors and Agnona. She was a Magnum Cum Laude graduate of the University of Texas with a
Bachelor of Science degree in Business Administration.
Management (cont.)
Anna Rhodes, Executive VP Operations
Ms. Rhodes has been actively involved in the cosmetic and cosmeceuticals industries for over 9 years. From
2001 through 2009, Ms. Rhodes held various executive sales and marketing positions with Victor
Cosmeceuticals, Inc. and Victor Products Inc., developing marketing and collateral materials, formulations and
training materials for new product launches as well as managing domestic and international distribution. Prior
to 2001, Ms. Rhodes held corporate executive managerial and sales positions in the high fashion industry with
companies including Calvin Klein, Alberta Ferretti, Michael Kors and Agnona. She was a Magnum Cum
Laude graduate of the University of Texas with a Bachelor of Science degree in Business Administration.
35
Board of Advisors
Dr J ames Andrews, Sports Orthopedics Andrews Institute for Sports Medicine
Dr J oshua Hackel, Andrews Sports Medicine Center, Florida
Dr Sydney Coleman, Plastic Surgeon, New York
Dr Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr Anthony Maddalo, Orthopedic Surgeon, NY Rangers
Dr Nicholas Toscano, Periodontitis, Editor in Chief J IAD
Dr Peter Bruno, Internist, New York City
Fred Frank Vice-Chairman PJ Solmon, former Merrill Lynch healthcare banker
J ack Schneider, former President Allen & Co.
Dr Eric Richter, Neurologist, Chief LSU
36
Board of Directors
Dr Steven Victor, Chairman & CEO, IntelliCell BioSciences
Leonard Mazur, COO Triax, former EVP Sales & Marketing, Medicis
Michael Hershman, Founder and CEO the Fairfax Group
Myron Houbliak, former President Roche Therapeutics Inc.
Sam Khashman, CEO of Imagine Technologies
37
Scientific Advisory Board (SAB)
To assist the company in its clinical development programs, IntelliCell
has assembled a scientific advisory board consisting of world-renowned
researchers and experts in the field of Regenerative Medicine:
Professor J oachim Kohn (Rutgers University)
Professor J on Dobson (University of Florida)
Professor J ared Bushman (Rutgers University)
Professor Laith J azrawi (New York University)
Subject Matter Specialists
Biologics Consulting Group
Andra E. Miller Ph.D. - Senior Consultant, Director Cell and Gene Therapies. 9 years
experience as a molecular biologist and product reviewer with the FDA.
Stephen Rhodes M.S. - Senior Consultant. Over 20 years of management experience with
the FDA Center for Devices and Radiological Health.
Holly Scott - Senior Consultant. 20 years of multi-office compliance experience with the
FDA, including 4 years as a Consumer Safety Officer with FDA/CBER, and 15 years as a
Field Investigator with the FDA Office of Regulatory Affairs/ Florida District Office.
Buchanan Ingersoll & Rooney, PC
Edward John Allera focuses on the development of new products and business
opportunities in the areas of pharmaceuticals and technology, especially regarding the
regulation and promotion of drugs, biologics and devices.
Theodore M. Sullivan counsels clients subject to FDA regulations, advising in matters
related to over-the-counter drug regulation, drug exclusivity issues, food and dietary
supplement labeling and advertising and import detention of FDA-regulated products.
38